Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Intervention with Acalabrutinib in High-Risk CLL
NCT04660045Phase 2Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- May 2022
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), sponsored by Weill Cornell Medicine. Planned start May 2022; status: withdrawn.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04660045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660045.